hydroxyethylrutoside

Hydroxyethylrutoside, also known as oxerutins, is a standardized mixture of semi-synthetic flavonoids derived from rutin. It is classified as a venoactive or phlebotonic agent used primarily to treat symptoms of chronic venous insufficiency (CVI), such as edema, pain, and heavy legs. The drug acts by reducing capillary hyperpermeability and increasing venous tone, which helps to stabilize the vascular endothelium and prevent the leakage of fluid into surrounding tissues. It also exhibits antioxidant and anti-inflammatory properties by scavenging reactive oxygen species and inhibiting leukocyte activation. Historically part of the Novartis and GSK consumer healthcare portfolios, the brand Venoruton was divested to Stada in 2020. It has also been investigated in clinical trials for the prevention of post-thrombotic syndrome (PTS) following deep vein thrombosis (DVT).

Brand names

VenorutonParovenRelvène

Other names

hydroxyethylrutosideoxerutinsO-(beta-hydroxyethyl)-rutosidesHR